Spero Therapeutics Inc (SPRO) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/08/20
Spero Therapeutics Announces First Quarter 2020 Operating Results and Provides Business UpdateGlobeNewsWire • 05/08/20
Spero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract InfectionGlobeNewsWire • 05/05/20
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/30/20
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/31/20
Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) InfectionGlobeNewsWire • 03/11/20
Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q4 Earnings Expected to DeclineZacks Investment Research • 03/05/20
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 02/28/20
Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr DevelopmentGlobeNewsWire • 02/05/20
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/31/20
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary DiseaseGlobeNewsWire • 12/04/19
Spero Therapeutics - Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 11/29/19
Spero Therapeutics (SPRO) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/30/19